You may experience different side effects from compounded semaglutide than from FDA-approved semaglutide, whether due to dosing errors or added ingredients that compounding pharmacies sometimes add
Compounded medications are prepared by PCAB/NABP-accredited pharmacies and are not FDA-approved for safety, efficacy, or quality
Elevated amylase and lipase levels in patients using glucagonlike peptide-1 receptor agonists or dipeptidyl-peptidase-4 inhibitors in the outpatient setting
Now this sounds absolutely fantastic at surface level, and even the writer of this article can see that this could probably be helpful in treating diabetes
So far, studies have reported: Phase 2 (48 weeks): up to 24.2% average weight loss Phase 3 TRIUMPH-4 topline (68 weeks): 28.7% average weight loss (press release) What that looks like: If you start at 100 kg : 24.2% 24 kg average loss 28.7% 29 kg average loss Side effects and safety signals (what we know so far) Phase 2 (peer-reviewed) In the phase 2 trial, the most common adverse events were gastrointestinal and dose-related, typically mild to moderate